Inefficacy of selegiline in treatment of canine pituitary-dependent hyperadrenocorticism

Aust Vet J. 2004 May;82(5):272-7. doi: 10.1111/j.1751-0813.2004.tb12702.x.


Objective: To evaluate selegiline, a monoamine oxidase-B inhibitor, for treating dogs with pituitary-dependent hyperadrenocorticism.

Design: Prospective clinical trial using client-owned dogs with pituitary-dependent hyperadrenocorticism treated at The University Veterinary Centre, Sydney, from September 1999 to July 2001.

Procedure: Eleven dogs with pituitary-dependent hyperadrenocorticism treated with selegiline were monitored at days 10, 30 and 90 by clinical examination, tetracosactrin stimulation testing, urinary corticoid:creatinine ratio measurement and client questionnaire. Endogenous adrenocorticotropic hormone measurements were also performed on most dogs on days 0 and 90. No dog treated with selegiline had satisfactory control of disease.

Conclusion: Selegiline administration was safe and free of side-effects at the doses used, but did not satisfactorily control disease in pituitary-dependent hyperadrenocorticism affected dogs.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Oral
  • Adrenal Cortex Function Tests / veterinary
  • Adrenocortical Hyperfunction / drug therapy
  • Adrenocortical Hyperfunction / veterinary*
  • Animals
  • Dog Diseases / drug therapy*
  • Dog Diseases / pathology
  • Dog Diseases / urine
  • Dogs
  • Female
  • Male
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / therapeutic use*
  • Prospective Studies
  • Selegiline / administration & dosage
  • Selegiline / therapeutic use*
  • Surveys and Questionnaires
  • Treatment Outcome


  • Neuroprotective Agents
  • Selegiline